Controversies in the treatment of Parkinson's disease

Current Opinion in Neurology

Volumn 9, Issue 4, 1996, Pages 308-313

  Hely, Mariese A ^a   Morris, John G L ^a  

^a WESTMEAD HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BROMOCRIPTINE; CABERGOLINE; CATECHOL METHYLTRANSFERASE INHIBITOR; DOPAMINE RECEPTOR STIMULATING AGENT; ENTACAPONE; LEVODOPA; PERGOLIDE; SELEGILINE; TOLCAPONE;

ANIMAL EXPERIMENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG FATALITY; DRUG MECHANISM; DYSKINESIA; HUMAN; MAJOR CLINICAL STUDY; MORTALITY; MULTICENTER STUDY; NONHUMAN; PARKINSON DISEASE; RANDOMIZED CONTROLLED TRIAL; RAT; REVIEW; SINGLE BLIND PROCEDURE;

EID: 0029785032     PISSN: 13507540     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019052-199608000-00012     Document Type: Review

References (43)

1. Mena MA, Pardo B, Casarejos MJ, Fahn S, Garcia de Yebenes J: Neurotoxicity of levodopa on catecholamine-rich neurons. Mov Disord 1992, 7:23-31.
2. Fahn S, Cohen G: The oxidant stress hypothesis in Parkinson's disease: evidence supporting it. Ann Neurol 1992, 32:804-812.
3. Hoehn MM: Parkinson's disease: progression and mortality. Adv Neurol 1986, 45:457-461.
4. Clarke CE: Does levodopa therapy delay death in Parkinson's disease? A review of the evidence. Mov Disord 1995, 10:250-256. This is a review of mortality in Parkinson's disease in the eras before and after levodopa. Current mortality rates are comparable with those before levodopa. When levodopa was first introduced, death was delayed in a cohort of frail elderly patients. By the late 1970s, however, their death rate overlapped with the normal death rate leading to an apparent increase in mortality. This has not been sustained.
5. Birkmayer W, Knoll J, Riederer P, Youdim MBH, Hars V, Marton J: Increased life expectancy resulting from addition of L-deprenyl to Madopar treatment in Parkinson's disease: a long term study. J Neurol Transm 1985, 64:113-127.
6. Cohen G, Pasik P, Cohen B, Leist A, Mytilineou C, Yahr MD: Pargyline and deprenyl prevent the neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in monkeys. Eur J Pharmacol 1985, 106:209-210.
7. Olanow CW, Hauser RA, Gauger L, Malapira T, Koller W, Hubble J, Bushenbark K, Lilienfeld D, Esterlitz J: The effect of deprenyl and levodopa on the progression of Parkinson's disease. Ann Neurol. 1995, 38:771-777.
8. Lange KW, Riederer P, Youdim MB: Biochemical actions of L-deprenyl (selegiline). Clin Pharmacol Ther 1994, 56:734-741.
9. Tatton WG: Selegiline can mediate neuronal rescue rather than neuronal protection. Mov Disord 1993, 8(suppl 1):S20-S30.
10. Tetrud JW, Langston JW: The effect of deprenyl (selegiline) on the natural history of Parkinson's disease. Science 1989, 245:519-522.
11. The Parkinson Study Group: Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 1993, 328:176-183.
12. Myllylä VV, Heinonen EH, Vuorinen JA, Kilkku OI, Sotaniemi KA: Early selegiline therapy reduces levodopa dose requirement in Parkinson's disease. Acta Neurol Scand 1995, 91:177-182.
13. Allain H, Pollak P, Neukirch HC and members of the French Selegiline Multicentre Trial: Symptomatic effect of selegiline in de novo Parkinsonian patients: Mov Disord. 1993, 8(suppl 1):S36-S40.
14. Brannan T, Yahr MD: Comparative study of selegiline plus L-dopa-carbidopa versus L-dopa-carbidopa alone in the treatment of Parkinson's disease. Ann Neurol 1995, 37:95-98.
15. Elizan TS, Moros DA, Yahr MD: Early combination of selegiline and low-dose levodopa as initial symptomatic therapy in Parkinson's disease. Experience in 26 patients receiving combined therapy for 26 months. Arch Neurol 1991, 48:31-34.
16. Parkinson Study Group: DATATOP: a multicentre controlled clinical trial in early Parkinson's disease. Arch Neurol 1989, 46:1052-1060.
17. Ward CD: Does selegiline delay progression of Parkinson's disease? A critical re-evaluation of the DATATOP study. J Neurol Neurosurg Psychiatry 1994, 57:217-220.
18. Baronti F, Davis TL, Boldry RC, Mouradian MM, Chase TN: Deprenyl effects on levodopa pharmacodynamics, mood, and free radical scavenging. Neurology 1992, 42:541-544.
19. Lees AJ on behalf of the Parkinson's Disease Research Group of the UK: Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease. BMJ 1995, 311:1602-1607. This is a controversial, large, long-term study that reported an increased mortality in patients given selegiline with levodopa compared with patients on levodopa alone when analysed on an intention to treat basis. It has cast doubt on the chronic, widespread use of selegiline in Parkinson's disease.
20. Parkinson Study Group: Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP subjects not requiring levodopa. Ann Neurol 1996, 39:29-36.
21. Parkinson Study Group: Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP patients requiring levodopa. Ann Neurol 1996, 39:37-45. These two references show the need for prolonged follow-up when progression of disease and late side effects are being studied.
22. Sivertsen B, Dupont E, Mikkelsen B, Mogensen P, Rasmussen C, Boesen F, Heinonen E: Selegiline and levodopa in early or moderately advanced Parkinson's disease: a double-blind control short- and long-term study. Acta Neurol Scand 1989, 126:147-152.
23. Parkinson's Disease Research Group in the UK: Comparison of therapeutic effects of levodopa, levodopa and selegiline, and bromocriptine in patients with early, mild Parkinson's disease: three year interim report. BMJ 1993, 307:469-472.
24. Hely MA, Morris JGL, Reid WGJ, O'Sullivan DJ, Williamson PM, Broe GA, Adena MA: Age at onset: the major determinant of outcome in Parkinson's disease. Acta Neurol Scand 1995, 92:455-463. This provides an assessment of the influence of clinical features at presentation in de-novo patients on the later course of Parkinson's disease from data collected in the Sydney Multicentre study [33].
25. Pezzoli G, Martignoni E, Pacchetti C, Angelen V, Lamberti P, Muratorio A, Bonuccelli U, De Mari M, Foschi N, Cossutta E et al: A crossover, controlled study comparing pergolide with bromocriptine as an adjunct to levodopa for the treatment of Parkinson's disease. Neurology 1995, 45(suppl 3):S22-S27.
26. Wolters E, Tissingh G, Bergmans PLM, Kuiper MA: Dopamine agonists in Parkinson's disease. Neurology 1995, 45(suppl 3):S28-S34.
27. Olanow CW, Fahn S, Muenter M, Klawans H, Hurtig H, Stern M, Shoulson I, Kurlan R, Grimes JD, Jankovic J et al: A multicentre double-blind placebo-controlled trial of pergolide as an adjunct to Sinemet in Parkinson's disease. Mov Disord 1994, 9:40-47.
28. Mizuno Y, Kondo T, Narabayashi H: Pergolide in the treatment of Parkinson's disease. Neurology 1995, 45(suppl 3):S13-S21.
29. Bonnet AM, Serre I, Marconi R, Agid Y, Dubois B: A 'combined' levodopa test as a useful method evaluating the efficacy of dopamine agonists: application to pergolide and bromocriptine. Mov Disord 1995, 10:668-671. This is a well designed study directly comparing bromocriptine and pergolide added to levodopa in patients with dyskinesias and fluctuations. Pergolide was found to be more efficacious than bromocriptine.
30. Inzelberg R, Nisipeanu P, Rabey MJ, Korczyn AD: Long-term tolerability and efficacy of cabergoline, a new long-acting dopamine agonist, in Parkinson's disease. Mov Disord 1995, 10:604-607.
31. Ahlskog JE, Muenter MD, Maraganore DM, Matsumoto JY, Lieberman A, Wright KF, Wheeler K: Fluctuating Parkinson's disease. Treatment with the long-acting dopamine agonist cabergoline. Arch Neurol 1994, 51:1236-1241.
32. Rinne UK: Combined bromocriptine-levodopa therapy early in Parkinson's disease. Neurology 1985, 35:1196-1198.
33. Hely MA, Morris JGL, Reid WGJ, O'Sullivan DJ, Williamson PM, Rail D, Broe GA, Margrie S: The Sydney Multicentre Study of Parkinson's disease: a randomised prospective five year study comparing low dose bromocriptine with low dose levodopa-carbidopa. J Neurol Neurosurg Psychiatry 1994, 57:903-910.
34. Montastruc JL, Rascol O, Senard JM, Rascol A: A randomised controlled study comparing bromocriptine to which levodopa was later added, with levodopa alone in previously untreated patients with Parkinson's disease: a five year follow up. J Neurol Neurosurg Psychiatry 1994, 57:1034-1038.
35. Jenner P: The rationale for the use of dopamine agonists in Parkinson's disease. Neurology 1995, 45(suppl 3):S6-S12. This is a useful review of the mechanisms by which dopamine agonists may be neuroprotective in Parkinson's disease.
36. Chase TN, Engber TM, Mouradian MM: Palliative and prophylactic benefits of continuously administered dopaminomimetics in Parkinson's disease. Neurology 1994, 44(suppl 6):S15-S18.
37. Felten DL, Felten SY, Fuller RW: Chronic dietary pergolide preserves nigrostriatal neuronal integrity in aged Fischer 344 rats. Neurobiol Aging 1992, 13:339-351.
38. Lange KW, Rausch WD, Gsell W, Naumann M, Oestreicher E, Riederer P: Neuroprotection by dopamine agonists. J Neural Transm Suppl 1994, 43:183-201.
39. Przuntek H, Welzel D, Blümner E, Danielczyk W, Letzel H, Kaiser H-J, Kraus PH, Riederer P, Schwarzmenn D, Wolf H, Liberia K: Bromocriptine lessens the incidence of mortality in L-dopa-treated Parkinsonian patients: Prado-Study discontinued. Eur J Clin Pharmacol 1992, 43:357-363.
40. Mars H: Modification of levodopa effect by systemic decarboxylase inhibition. Arch Neurol 1973, 28:91-95.
41. Davis TL, Roznoski M, Burns RS: Effects of tolcapone in Parkinson's patients taking L-dihydroxyphenylalanine/carbidopa and selegiline. Mov Disord 1995, 10:349-351.
42. Merello M, Lees AJ, Webster R, Bovingdon M, Gordin A: Effect of entacapone, a peripherally acting catechol-O-methyltransferase inhibitor, on the motor response to acute treatment with levodopa in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 1994, 57:186-189.
43. Kaakkola S, Teräväinen H, Ahtila S, Rita H, Gordin A: Effect of entacapone, a COMT inhibitor, on clinical disability and levodopa metabolism in Parkinsonian patients. Neurology 1994, 44:77-80.